Akamis Bio
London, United Kingdom · Founded 2020 · $90.0M raised
- Headquarters
- London
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- akamisbio.com
- Total Funding
- $90.0M
- Last Round
- $60.0M Series ADec 2024
- Rounds
- 2
About
Akamis Bio is a UK clinical-stage biotech developing oncolytic immunotherapies targeting colorectal cancer using its proprietary T-SIGn platform.
Summary
Akamis Bio is a Biotech company based in London, United Kingdom, founded in 2020. It has raised $90.0M in total across 2 rounds, most recently a $60.0M Series A round in Dec 2024. Investors include Sedgwick Yard, ARCH Venture Partners and Parker Institute for Cancer Immunotherapy.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...